[{"from": "human", "value": "Could you provide a description of this molecule? [C][C][C@H1][Branch1][C][C][C@@H1][Branch2][=N][#C][C][=Branch1][C][=O][N][C@H1][C][S][S][C][C@H1][Branch2][O][O][N][C][=Branch1][C][=O][C@@H1][Branch2][#Branch2][=Branch2][N][C][=Branch1][C][=O][C@@H1][Branch2][=Branch2][Branch2][N][C][=Branch1][C][=O][C@@H1][Branch2][Branch2][=C][N][C][=Branch1][C][=O][C][N][Branch2][Branch2][Ring1][C][=Branch1][C][=O][C@@H1][Branch2][=Branch1][=N][N][C][=Branch1][C][=O][C@@H1][Branch2][Branch1][=C][N][C][=Branch1][C][=O][C@@H1][Branch2][Ring2][=C][N][C][=Branch1][C][=O][C@@H1][Branch2][Ring1][Ring2][N][C][=Branch1][C][=O][C@@H1][Branch1][#Branch1][N][C][Ring2][Ring2][N][=O][C][Branch1][C][C][C][C][C][=C][N][Branch1][O][C][=C][C][=C][C][=C][Ring1][=Branch1][Ring1][=Branch2][C][C][C][C][=Branch1][C][=O][N][C][C][=Branch1][C][=O][O][C][C][=C][N][C][=C][C][=C][C][=C][Ring1][=Branch1][Ring1][=Branch2][C][C][C][C][=C][N][=C][N][Ring1][Branch1][C][C][C][N][C][=Branch1][C][=N][N][C][=Branch1][C][=O][N][Branch1][C][C][C@@H1][Branch1][#Branch1][C@@H1][Branch1][C][C][C][C][C][=Branch1][C][=O][N][N][C][=Branch1][C][=O][C@@H1][Branch1][=N][C][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][O][N]"}, {"from": "gpt", "value": "The molecule is a compstatin-based inhibitor of human complement component C3, with potential use as a treatment for various diseases in which excessive complement activation plays a key role, including paroxysmal nocturnal hemoglobinuria (PNH) and complement 3 glomerulopathy (C3G). Upon administration, C3 complement inhibitor AMY-101 selectively binds to C3 and inhibits C3 activity. This prevents complement pathway activation, and inhibits complement-mediated inflammation and cell lysis. Excessive complement activation plays a key role in various inflammatory and autoimmune diseases, and leads to tissue destruction. C3 is a crucial and central component of the complement system, and the complement system is an integral component of the innate immune response."}]